Rimegepant ni ntoya ya molekile inhibitor yacalcitoninreseptor ya gene ifitanye isano na peptide (CGRP) ihagarika ibikorwa bya CGRP, vasodilator ikomeye yizeraga ko igira uruhare mukubabara umutwe wa migraine. Rimegepant yemerewe kuvura ibitero bikaze bya migraine. Mu bigeragezo byo kwa muganga, rimegepant muri rusange yihanganiye gusa ibihe bidasanzwe byo kuzamuka kwa serumu by'agateganyo aminotransferase mu gihe cyo kuvura kandi nta na hamwe byagaragaye ko byakomeretse umwijima.

Rimegepant ni umunwa urwanya reseptor ya CGRP yakozwe na Biohaven Pharmaceuticals. Yakiriye FDA ku ya 27 Gashyantare 2020 yo kuvura indwara ya migraine ikabije. Mugihe ababyeyi benshi barwanya CGRP hamwe niyakirwa ryayo bemerewe kuvura migraine (urugero: erenumab], [fremanezumab], [galcanezumab]), rimegepant na [ubrogepant] ni bo bonyine bagize umuryango wa "gepants" imiti isigaye mu iterambere, hamwe na CGRP yonyine barwanya bioavailable yo mu kanwa. Ubu buryo bwo kuvura migraine burimo kuvura gukuramo inda hamwe na "triptans", nka [sumatriptan], ariko iyi miti irabujijwe ku barwayi bafite indwara zifata ubwonko n'ubwonko bw'imitsi mbere na mbere bitewe n'imiterere ya vasoconstrictive. Antagonism yinzira ya CGRP yahindutse intego ishimishije yo kuvura migraine kuko, bitandukanye na triptans, umunwa wa CGRP wo mu kanwa ntabwo wigeze ubona imitsi ya vasoconstrictive bityo ukaba ufite umutekano muke mukoresha abarwayi bafite imiti ivura imiti isanzwe.

Rimegepant ni aCalcitoninGene ifitanye isano na Peptide Receptor Antagonist. Uburyo bwibikorwa bya rimegepant ni nka aCalcitoninGene ifitanye isano na Peptide Receptor Antagonist.